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background: We compared cardiovascular (CV) events between high-risk patients achieving an LDL particle (LDL-P) target <1000 nmol/L versus 
an LDL cholesterol (LDL-C) target <100 mg/dL among a large commercially insured US population.
methods: Adult patients were selected from the HealthCore Integrated Research DatabaseSM. High-risk patients who achieved LDL-P <1000 
between 1/1/2006 and 9/30/2012 were placed into the LDL-P cohort with the index date being the earliest observed LDL-P target. Patients 
without LDL-P measurements, but who achieved LDL-C <100, were placed into the LDL-C cohort. Baseline patient characteristics were assessed 6 
months pre-index and patients were followed for 12-36 months post-index. Propensity score matching was used to balance pre-index demographic 
and comorbidity differences between cohorts while leaving treatment patterns intact.
results: Matched LDL-P and LDL-C patients were balanced with respect to demographics and comorbidities. LDL-P patients were more likely to 
receive higher potency statins at baseline. During 12-36 months follow-up, LDL-P patients had fewer CV events versus LDL-C patients (36 month HR= 
0.75; 95% CI 0.58-0.97).
conclusion: In this real-world sample of commercially insured patients, results suggest that patients achieving LDL-P <1000 received more 
aggressive lipid-lowering treatment than patients achieving LDL-C <100, and that these treatment differences are associated with a reduction in CV 
event rates over 12-36 months follow-up.
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Baseline Characteristics
Age, mean (± SD) 56.9 (10.6) 56.3(10.9) 0.055 56.8 (10.6) 56.0 (11.1) 0.054 56.7 (10.5) 56.6 (10.7) 0.872
Female, n (%) 899 (42.9) 881 (42.1) 0.574 526 (42.4) 539 (43.4) 0.598 302 (42.8) 320 (45.4) 0.334
Diabetes mellitus, n (%) 1,183 (56.5) 1,198 (57.2) 0.640 692 (55.7) 715 (57.6) 0.352 407 (57.7) 408 (57.9) 0.957
Cardiovascular disease, n (%) 1,313 (62.7) 1,279 (61.1) 0.279 778 (62.6) 776 (62.5) 0.934 425 (60.3) 396 (56.2) 0.117
Comorbidity score, mean (± SD) 1.04 (1.3) 1.12 (1.2) 0.043 1.03 (1.3) 1.10 (1.3) 0.175 1.04 (1.2) 1.07 (1.2) 0.616
Lipid-lowering medications, n 
(%) with ≥1 fill
1,524 (72.8) 1,464 (69.9) 0.040 912 (73.4) 838 (67.5) 0.001 500 (70.9) 485 (68.8) 0.384
Statin potency level 3, n (%) 383 (18.3) 484 (23.1) 0.000 230 (18.5) 259 (20.9) 0.158 123 (17.5) 158 (22.4) 0.020
Statin potency level 4, n (%) 794 (37.9) 706 (33.7) 0.005 460 (37.0) 423 (34.1) 0.001 252 (35.7) 229 (32.5) 0.196
Statin potency level 5, n (%) 236 (11.3) 125 (6.0) <.001 136 (11.0) 63 (5.1) <.001 72 (10.2) 24 (3.4) <.001
LDL-P, mean (± SD) 858.3 (106.3) N/A N/A 861.9 (105.4) N/A N/A 864.2 (105.5) N/A N/A
LDL-C, mean (± SD) 72.6 (20.5) 78.8 (14.6) <.001 73.4 (21.1) 79.5 (14.1) <.001 73.3 (21.9) 79.3 (14.7) <.001
HDL-C, mean (± SD) 54.0 (15.2) 48.4 (13.9) <.001 52.7 (14.4) 47.4 (13.2) 0.001 52.1 (14.1) 48.7 (14.3) 0.001
Follow-up CV Event Risk
≥1 event, n (%) 131 (6.26) 170 (8.12) 0.020 136 (11.0) 173 (13.9) 0.025 103 (14.6) 134 (19.0) 0.027
Events, mean (± SD) 0.10 (0.50) 0.11 (0.46) 0.026 0.19 (0.70) 0.26 (0.90) 0.027 0.28 (0.86) 0.34 (0.87) 0.031
Hazard Ratio (95% CI) 0.75 (0.46-0.98) 0.012 0.78 (0.62-0.97) 0.028 0.75 (0.58-0.97) 0.029
